Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection

New England Journal of Medicine

Volumn 349, Issue 24, 2003, Pages 2293-2303

  Robbins, Gregory K ^a,p   De Gruttola, Victor ^b   Shafer, Robert W ^c   Smeaton, Laura M ^b   Snyder, Sally W ^d   Pettinelli, Carla ^e   Dubé, Michael P ^f   Fischl, Margaret A ^g   Pollard, Richard B ^h   Delapenha, Robert ⁱ   Gedeon, Linda ^j   Van Der Horst, Charles ^k   Murphy, Robert L ^l   Becker, Mark I ^m   D'Aquila, Richard T ⁿ   Vella, Stefano ^o   Merigan, Thomas C ^c   Hirsch, Martin S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ HOWARD UNIVERSITY   (United States)

^j FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^k UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^l NORTHWESTERN UNIVERSITY   (United States)

^m AGOURON PHARMACEUTICALS INC   (United States)

ⁿ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^o ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^p MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NELFINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INITIAL THERAPY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT FAILURE; VIRUS INHIBITION;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NELFINAVIR; OXAZINES; RNA, VIRAL; STAVUDINE; TIME FACTORS; TREATMENT FAILURE; ZIDOVUDINE;

EID: 0345012053     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa030264     Document Type: Article

References (16)

1. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:222-35.
2. Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Accessed November 12, 2003, at http://www.aidsinfo.nih.gov/guidelines/adult/archive/AA_071403.html.)
3. Pozniak A, Gazzard B, Anderson J, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003;4:Suppl 1:S1-S41.
4. Division of AIDS. Division of AIDS table for grading severity of adult adverse experiences. Rockville, Md.: National Institute of Allergy and Infectious Diseases, 1992.
5. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2304-15.
6. Smeaton LM, DeGruttola V, Robbins GK, Shafer RW. ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1. Control Clin Trials 2001;22:142-59.
7. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care 2000;12:255-66.
8. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34:585-612.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
10. Proportional hazards model. In: Cox DR, Oakes D. Analysis of survival data. New York: Chapman and Hall, 1984:97-110.
11. Analysis of variance and regression. In: Casella G, Berger RL. Statistical inference. 2nd ed. Pacific Grove, Calif.: Duxbury/Thomson Learning, 2002:521-63.
12. Fitting loglinear and logit models. In: Agresti A. Categorical data analysis. New York: Wiley, 1990:165-99.
13. Havlir DV, Gilbert PB, Bennett K, et al. Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. AIDS 2001;15:1379-88.
14. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16:2165-73.
15. Gulick RM, Mellors JW, Havlir D, et al. 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000;133:35-9.
16. Staszewsiki S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999;341:1865-73.